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AbstrAct
Objectives (1) Hypothesis testing of the potency of 
rituximab (RTX) in preventing fibrotic complications and 
(2) assessing acceptability and feasibility of RTX in early 
systemic sclerosis (SSc).
Methods A small, 24-month, randomised, double-blind, 
placebo-controlled, single-centre trial in patients with SSc 
diagnosed <2 years was conducted. Patients received RTX 
or placebo infusions at t=0, t=15 days and t=6 months. 
Patients were clinically evaluated every 3 months, with 
lung function tests and high-resolution CT every other 
visit. Skin biopsies were taken at baseline and month 3. 
Immunophenotyping of peripheral blood mononuclear cells 
was performed at every visit, except at months 9 and 18. 
Adverse events, course of skin and pulmonary involvement 
and B cell populations in skin and peripheral blood were 
evaluated.
Results In total 16, patients (rituximab n=8, placebo n=8) 
were included. Twelve patients had diffuse cutaneous SSc. 
Eighty-eight adverse events (RTX n=53, placebo n=35, 
p=0.22) and 11 serious adverse events (RTX n=7, placebo 
n=4, p=0.36) occurred. No unexpected RTX-related events 
were observed. Mean skin score over time did not differ 
between the groups. Over time, forced vital capacity and 
extent of lung involvement slightly improved with RTX, but 
this difference was insignificant. In peripheral blood B cells 
depletion was demonstrated.
Conclusions No unexpected safety issues were observed 
with RTX in early SSc. Although this small trial could not 
confirm or reject potential efficacy of RTX in these patients, 
future placebo-controlled trials are warranted, specifically 
in the subgroup of patients with pulmonary involvement.
Trial registration number EudraCT 2008-07180-16; 
Results.
IntroductIon
Systemic sclerosis (SSc) is an autoimmune 
disease that is characterised by the triad 
of microvascular damage, dysregulation of 
innate and adaptive immunity and gener-
alised fibrosis in multiple organs.1
The pathogenesis of SSc is poorly under-
stood and treatment is organ and symptom 
based. Current therapy targeting the dysreg-
ulated immune system, supported by clinical 
trial data, includes methotrexate for early skin 
involvement,2 3 cyclophosphamide followed 
by mycophenolate mofetil or azathioprine 
for lung involvement4–8 and autologous 
haematopoietic stem cell transplantation for 
severe, diffuse cutaneous systemic sclerosis 
(dcSSc).9
Experimental data suggested a key role for 
B cells in the pathogenesis of SSc.10 B cells 
seem to overexpress the stimulatory receptor 
CD19 and interleukin-10-producing regula-
tory B cells are decreased.11
Previous observational open-label studies 
of anti-CD20 therapy (rituximab (RTX)) and 
a nested case–control study in SSc showed 
potential efficacy for skin disease and stabili-
sation of internal organ disease in dcSSc.12–21 
Since natural disease course is variable and 
difficult to predict, these results are diffi-
cult to value and need to be replicated in 
randomised controlled trials (RCTs).22
Key messages
What is already known about this subject?
 ► In the tight-skin mouse model of systemic sclerosis, 
anti-CD20 therapy suppresses development of skin 
fibrosis in newborn tight-skin mice.
 ► Open-label studies in patients with systemic sclerosis 
showed possible clinical benefit of rituximab on skin 
and lung involvement.
 ► In systemic sclerosis patients, rituximab treatment 
results in depletion of CD20-positive B cells from 
peripheral blood and skin.
What does this study add?
 ► This study reports data on the course of skin and lung 
involvement in patients with early systemic sclerosis 
patients that participated in a small randomised 
placebo-controlled phase II trial with rituximab.
 ► Rituximab might be of benefit for pulmonary 
involvement in early systemic sclerosis.
 ► Immunologic analyses demonstrate depletion of 
the different B cell subsets from peripheral blood; 
immunohistological analyses show that the number 
of B cells present in skin is low, and also after 
treatment with rituximab, CD79 positive cells remain.
How might this impact on clinical research?
 ► A larger phase III trial of rituximab in patients with 
early systemic sclerosis and pulmonary involvement 
can be considered.
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We hypothesised that the window of opportunity for 
rituximab (RTX) in patients with SSc lies early in the 
disease course, when fibrotic complications are yet to 
develop. This hypothesis is based on observations in a 
study in mice in which B cell depletion with anti-CD20 
was effective in prevention of skin fibrosis in newborn 
tight-skin mice while no benefit was observed in tight skin 
mice with established disease.23 Additionally, B cell acti-
vating factor (BAFF) levels in these mice were elevated 
at 4 weeks after birth, while normalised at week 12 when 
skin fibrosis was established.24
Based on these observations, we aimed to test the 
hypothesis that RTX can prevent development of severe 
fibrotic complications in early SSc. Additionally, safety 
and feasibility of RTX in early SSc is described, together 
with the influence of RTX on immune cell subsets in 
peripheral blood and in skin tissue in patients with SSc.
Methods
trial design
The RTX in early SSc trial was designed as a 24-month, 
parallel, double-blind, placebo-controlled randomised 
trial. Randomisation was performed in a 1:1 ratio by 
the Pharmacy of the Leiden University Medical Center 
(LUMC), Leiden, The Netherlands. Ethical approval was 
obtained from the Medical Ethical Committee (METC) 
of the LUMC and patients gave written informed consent. 
The study was monitored by a Data and Safety Monitoring 
Board until completion.
Patients
Between June 2010 and February 2014, patients with an 
established diagnosis of SSc according to the American 
Rheumatology Association (ARA) criteria25 within the 
last 24 months before enrolment and aged between 18 
and 70 years were included. Previous immunosuppressive 
therapy was allowed and continued throughout the trial. 
Patients with a history of deep tissue infection within 
1 year prior to baseline, patients with chronic or recur-
rent infections and patients with a history of cancer were 
excluded.
Procedures
Patients received intravenous 1000 mg RTX (MabThera/
Anti-CD 20 mAb) or placebo (0.9% NaCl) on day 1 and 
day 15 as induction treatment. Consolidation treatment 
consisted of a single intravenous treatment with 1000 mg 
RTX or placebo (0.9% NaCl) at 6 months. Each infusion 
of RTX was given together with intravenous methyl-
prednisolone 100 mg, oral paracetamol 1000 mg and 
intravenous clemastine 2 mg. Placebo-treated patients 
received 1.6 mL 0.9% NaCl together with oral paracetamol 
1000 mg and intravenous clemastine 2 mg. Concomitant 
medications or other treatments deemed necessary for 
patients’ supportive care and safety were allowed at the 
discretion of the treating physician. Patients, physicians 
and the observers performing the skin score were blinded 
for treatment allocation.
data collection
Patients were seen every 3 months during the first 
year and every 6 months thereafter, for physical exam-
ination including the modified Rodnan skin score 
(mRSS), and assessing toxicity (National Cancer Insti-
tute, common toxicity parameters),26 urinalyses and 
laboratory testing (at t=0, 3, 6, 12 and 24 months also 
including samples for immunophenotyping of periph-
eral blood) for a total follow-up of 24 months. Skin scores 
were assessed by an experienced research nurse (AV) 
and a research physician who was trained by AV (JM). 
In two-thirds of cases, the skin score was assessed by AV 
and in one-third by JM. Patients filled out the following 
questionnaires at every visit: Short Form 36 (SF-36),27 28 
EurolQol-5D (EQ-5D)29 30 and Health Assessment Ques-
tionnaire Disability Index (HAQ-DI).31 32 Lung function 
tests including forced vital capacity (FVC) and diffusing 
capacity of the lungs for carbon monoxide (DLCO), 
high-resolution CT (HRCT) of the thorax and echo-
cardiography were performed every 6 months. HRCTs 
were assessed using Goh criteria evaluating the extent of 
lung involvement at five levels: (1) origin of great vessels; 
(2) main carina; (3) pulmonary venous confluence; (4) 
halfway between the third and fifth section; (5) immedi-
ately above the right diaphragm.33 Scoring was performed 
consensus based, by two observers (AS and LK).
For histological and immunohistochemical analysis 
of the skin, 4 mm skin biopsies were obtained from the 
dorsal side of the forearm, within 1 cm of each other, at 
baseline and at 3 months.
Immunohistochemistry of skin tissue was performed 
on 4 µm thick sections on polysine-coated slides. After 
routine deparaffinisation and rehydration, antigens were 
retrieved in a tissue microwave for 12 min at 98°C with a 
Target Retrieval Solution (Tris)/EDTA pH 9. Quenching 
of endogenous peroxidase activity was performed with 
1% hydrogen peroxide in methanol for 10 min. Biop-
sies were incubated with: H&E staining (4085.9005 and 
4085.9002; Klinipath; Duiven, Netherlands) (general 
histopathology assessment and mononuclear infiltra-
tion), PBS/1%BSA for 1 hour with CD3 (1.41 µg/mL; 
M7254; DAKO) (T-cells), CD68 (0.12 µg/mL; M0814; 
DAKO) (macrophages), CD79a (1.875 µg/mL; M7050; 
DAKO) (B cells including plasma cells). Human tonsil 
specimens were used as a positive control for antibodies.
Stained sections were coded and scored by three 
observers who were unaware of clinical data and treat-
ment regimen (AD, KQ, MB) with respect to the following 
points: histological signs of scleroderma skin (such as 
presence and entrapment of adnexa), mononuclear 
infiltration (semiquantitative scale), T cell infiltration 
(semiquantitative scale), B cell infiltration (semiquantita-
tive scale) and macrophage infiltration (semiquantitative 
scale). Semiquantitative scoring for lymphocyte and 
macrophages was based on the scoring scale for lympho-
cytes proposed by Roumm et al with ‘0’ being a few 
scattered cells, ‘1’ a maximum number of cells per collec-
tion of at least 10, ‘2’ a maximum number of cells per 
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collection between 10 and 50 and ‘3’ a maximum number 
of cells per collection of at least 50.34 Median scores were 
used for analysis.
Peripheral blood mononuclear cells (PBMCs) were 
isolated from 50 mL of peripheral blood by Ficoll-Paque 
gradient centrifugation, incubated for 20 min at 4°C and 
subsequently stained with CD3 allophycocyanine (APC) 
(clone SK7), CD4 Fluorescein Isothiocyanate (FITC) 
(clone RPA-T4), CD8 phycoerythrin (PE) (clone RPA-T8), 
CD14 FITC (clone MSE2), CD16 PE (clone B73.1), 
CD19 PerCPcy5.5 and APC (clone Sj25C1), CD20 FITC 
(clone L27), CD27 PE (clone L128), CD38 PerCPcy5.5 
(clone HIT2), CD56 PE (clone MY31), Polyclonal IgA 
FITC (DAKO), IgD FITC (clone IA6-2), IgE Alexa Fluor 
488 (gift from University of Antwerp), IgG FITC (clone 
G18-145), IgM APC and FITC (clone G20-127, all (except 
IgA and IgE) BD Biosciences). For isotype controls, IgG1 
APC and PerCPcy5.5 (clone MOPC-21), IgG1 FITC 
and PE (clone X40), IgG2a FITC (clone X39), IgG2b 
FITC (clone 27–35), rabbit immunoglobulin fraction 
(DAKO) and polyclonal swine anti-rabbit immunoglob-
ulins FITC (DAKO), all (rabbit immunoglobulins) BD 
Biosciences, were used. In addition, B cells and plasmab-
lasts were stained with CD20, IgA, IgD, IgE, IgG, IgM and 
appropriate isotype controls.
Enzyme-linked immunosorbent spot (ELISPOT) tech-
nique was used to detect functional antibody-secreting 
cells, with the use of goat antihuman IgG, IgA and IgM 
(Sanbio BV, Uden, The Netherlands) for coating (10 µg/
mL in coating buffer, 100 µL/well) of ELISPOT plates 
(Millipore, The Netherlands). Plates were incubated 
overnight at 4°C, washed twice with PBS and blocked 
with 200 µL/well culture medium (Iscove's Modified 
Dulbecco's Medium(IMDM) +10% FCS+200 mM L-glu-
tamine+100 µg/mL penicillin/streptavidin) for 2 hours 
at 37°C in a 5% CO2 atmosphere. PBMCs were titrated 
on the ELISPOT plates in duplicate wells, and the plates 
were next incubated at 37°C in a 5% CO2 atmosphere 
overnight. The following day cells were discarded and 
washed from the plates with PBS/0.05% Tween 20 and 
tap water. Spots were visualised by detection with alka-
line phosphatase-conjugated goat antihuman IgG, IgM 
or IgA (Biosource, USA) followed by substrate 5-bromo-
4-chloro-3-indolyl phosphate/nitro blue tetrazolium 
(Sigma-Aldrich, St Louis, MO, USA) at 100 µL/well. ELIS-
POTs were analysed using a stereomicroscope (Bioreader 
5000; BIO-SYS GmbH, Karben, Germany).
study end points
In the design of the trial, the following parameters were 
defined as major clinical end points: treatment-related 
mortality, toxicity and clinical efficacy of rituximab. Efficacy 
was defined as progression-free survival, with progression 
defined as any or a combination of the following changes 
relative to baseline at two consecutive evaluations: 
death, ≥10% drop in predicted FVC,33 ≥15% drop in 
predicted DLCO,33 ≥15% drop in left ventricular ejection 
fraction (LVEF), body weight,35 ≥30% drop in creatinine 
clearance,36 ≥30% increase in mRSS,37 38 ≥0.5 point 
increase in HAQ-DI.38 The secondary end points defined 
were changes in mRSS (minimally important difference 
3.2–5.3),39 FVC, DLCO, HAQ-DI (minimally important 
difference 0.10–0.14),39 left ventricular ejection fraction, 
creatinine clearance, SF 36, EQ-5D, presence of intersti-
tial lung disease (ILD) as reported by HRCT thorax and 
skin biopsy scores.
However, unfortunately, the trial had major recruit-
ment problems. In a time span of nearly 4 years, 17 
patients had been included in the trial. Based on this 
low inclusion rate, the METC advised to prematurely 
end inclusion and evaluate study outcome 1 year after 
inclusion of the last patient. As one patient showed early 
dropout, n=16 patients (n=8 RTX, and n=8 placebo) had 
data available for analysis. All data collected by 30 June 
2015 were included in the analysis. Based on the small 
sample size, we chose to focus on presentation of changes 
in mRSS, FVC, DLCO and extent of ILD as represented 
by Goh scores. Adverse events and serious adverse events 
and changes in HAQ-DI, LVEF, creatinine clearance, 
SF-36, EQ-5D were assessed for both treatment groups. 
Immunologically, the influence of RTX on mononuclear 
cell subsets in PBMCs and skin tissue was evaluated and 
described as planned.
statistical analysis
As all patients participating in the trial also participated 
in the care programme of the LUMC,40 including annual 
and comprehensive diagnostic evaluation with informed 
consent for use of data, missing data were imputed from 
clinical files when possible with a maximum time frame 
of 6 months between data collection and planned data 
collection according to the trial schedule. This way, skin 
scores were available up to 24 months for all patients, 
pulmonary function tests for n=13/16 of patients at 
t=12 months and n=7/16 at t=24 months. HRCT images 
were available for scoring in n=15/16 at t=12 months 
and n=7/16 at t=24 months. Peripheral blood samples 
for PBMC assessment were available in n=15/18 at t=12 
months and n=11/18 at t=24 months.
Primary analyses included mean change over time 
in mRSS, percentage of predicted DLCO, percentage 
of predicted FVC, extent of ILD as represented by 
Goh scores and HAQ-DI, for both treatment groups. 
Additionally, mortality, treatment toxicity and efficacy 
according to prespecified criteria were evaluated for 
both groups.
Ninety-five per cent CIs were computed where appro-
priate, with p values less than 0.05 (two-sided) considered 
statistically significant. Binary variables were analysed by 
Fisher exact test.
To assess the influence on clinical efficacy analyses of 
patients included under protocol violation, analyses were 
repeated excluding these patients. Interobserver agree-
ment of skin biopsy scoring was evaluated using Fleiss’ 
kappa.41 Statistical analyses were performed using IBM 
SPSS Statistics 23 and GraphPad Prism 6.
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Figure 1 Flow of rituximab in early systemic sclerosis trial.  aOne patient refused to have a treatment at 6 months. bTwo 
patients incidentally received a dose of verum methylprednisolone instead of placebo methylprednisolone together with the 
RTX/placebo infusion.  RTX, rituximab; AE, adverse event; SAE serious adverse event.
results
Patients and treatment
From April 2010 to February 2014, 17 patients were 
included, of which nine patients were randomised to 
RTX and eight were randomised to placebo (figure 1). 
All patients included fulfilled ARA criteria as well as 
ACR/EULAR 2013 SSc criteria.42 Two patients were 
included with a time since diagnosis of >24 months: 
one RTX patient (time since diagnosis 3.5 years, time 
since non-Raynaud 3.5 years and time since Raynaud 5.3 
years) and one placebo patient (time since diagnosis 4.2 
years, time since non-Raynaud 4.2 years and time since 
Raynaud 4.9 years). One patient (placebo group) died 
due to disease progression, after dropout at 6 months 
because of active disease. One patient did not start the 
allocated treatment based on active, severe disease with 
rapid progression of skin score and myocarditis/pericar-
ditis, for which the treating physician judged the chance 
for placebo as possibly life-threatening. Baseline charac-
teristics of this patient did not differ from other patients 
included.
Baseline characteristics of the 16 patients included for 
analysis (RTX n=8, placebo n=8) were similar between 
the two groups, although there was a minor difference 
in disease duration, with slightly longer disease duration 
in the placebo group (table 1). The median follow-up of 
patients was 19.1 months (IQR 17.6–24.4). According to 
Goh criteria, mean extent of lung involvement at base-
line was 9.5%±11.0 for RTX and 6.9%±10.8 for placebo 
(p=0.65).
Previous immunosuppressive therapy included predni-
sone (RTX n=2, placebo n=1), methotrexate (RTX n=3, 
placebo n=0) and azathioprine (RTX n=2, placebo n=0). 
At start of the trial, use of immunosuppressive medi-
cation included prednisone (RTX n=2, placebo n=0), 
methotrexate (RTX n=5, placebo n=3), plaquenil (RTX 
n=1, placebo n=1) and mycophenolate mofetil (RTX=1, 
placebo n=1). During the trial background immunosup-
pressive treatment was changed in two patients in the RTX 
group: methotrexate was stopped at the 18-month visit in 
both cases (n=1: pregnancy; n=1: pancytopenia).
Analysis of clinical disease parameters
Course of changes in mRSS, FVC, DLCO and HAQ are 
shown in figure 2. There were no significant differences 
in change between baseline and 12-month follow-up 
of mRSS (placebo −1.8 vs RTX −3.6, p=0.95), FVC 
(placebo +0.3 vs RTX +4.7, p=0.43), DLCO (placebo 
−0.3 vs +0.7, p=0.91) and HAQ (placebo +0.18 vs RTX 
0.0, p=0.94). Also, at 24-month follow-up, there were no 
significant differences in change from baseline in mRSS 
(placebo −1.9 vs RTX −5.3, p=0.95), FVC (placebo −1.4 vs 
RTX+4, p=0.65), DLCO (placebo −2.2, RTX −6.0, p=0.77) 
and HAQ (placebo 0.2313 vs RTX −0.0675, p=0.94) 
results. Numerically, n=4/8 rituximab versus n=2/8 in 
placebo improved >5 points in mRSS; there were no 
improvers in either FVC or DLCO (minimal important 
difference 10%) and n=1/8 in RTX vs n=0/8 in placebo 
improved in HAQ (minimal important difference 0.5 
points) after 1 year.
Analysis of HRCT data according to Goh criteria 
showed a mean change in percentage of affected 
lung tissue between baseline and 12 months of −1.6% 
for RTX and +2.8% for placebo (p=0.28). Beneficial 
effects were explained by a decrease in ground glass 
opacities with RTX treatment in two RTX-treated 
patients (figures 3,4). Numerically, n=2/7 RTX 
patients and n=0/8 placebo patients showed improve-
ment on HRCT (−10% or more change in mean 
extent of lung involvement), n=4/7 in RTX versus 
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Table 1 Baseline characteristics of study patients
Characteristic
RTX group Placebo group
p-value(n=8) (n=8)
Demographic
  Age, mean (year) 44.5±5.6 36.6±4.3 0.21*
  Female sex (% of patients, n) 87.5 (7) 87.5 (7) 1†
  Caucasians (% of patients, n) 75 (6) 62.5 (5) 0.58†
Disease specific
  dcSSc (% of patients, n) 87.5 (7) 62.5 (5) 0.57†
  Duration of scleroderma (year)
    Since diagnosis (median, range) 0.9 (0.7–3.5) 1.3 (0.2–4.2) 0.444*
    Since onset first Raynaud symptom (median, range) 2.3 (0.7–5.3) 4.3 (0.7–16.1) 0.13*
    Since onset first non-Raynaud symptom (median, range) 1.2 (0.6–3.5) 2.4 (0.7–4.2) 0.25*
Skin and musculoskeletal
   Modified Rodnan skin score (mean±SE) 16.4±4.4 14.0±3.8 0.88*
Heart and lungs
  LVEF (mean±SE) 61.1±4.2 62.0±4.6 0.96*
  FVC (% of predicted) 97.9±6.6 92.0±6.1 0.67*
  DLCO (% of predicted) 67.1±4.2 72.3±6.0 0.34*
  Total extent of lung disease on HRCT¶ (mean %) 9.5±11.0 6.9±10.8 0.65*
  Extent ground glass (mean %) 8.3±9.4 5.4±8.0 0.44*
  Extent reticular pattern (mean %) 4.0±8.7 3.9±7.1 1*
Function and quality of life
  HAQ-DI (mean±SE) 1.39±0.27 1.31±0.32 0.65*
Therapy
  Previous immunosuppressive therapy‡ (% of patients) 50.0 12.5 0.28†
   months of use (median, range) 1.5 (0.0–36.0) 0.0 (0.0–9.0) 0.20*
  Immunosuppressive therapy§ (% of patients) 87.5 62.5 0.57†
   Months of use (median, range) 8.1 (0.0–42.6) 3.2 (0.0–26.3) 0.33†
Laboratory findings
  ANA-positive (% of patients) 100 87.5 1.00†
  Anti-topoisomerase I (% of patients) 12.5 50.0 0.28†
  Anti-RNA polymerase III (% of patients) 25.0 0.0 0.47†
*Mann-Whitney U test.
†Fisher's exact test.
‡Previous immunosuppressive therapy included high-dose (>15 mg/day) prednisone (RTX n=2, placebo n=1), methotrexate (RTX n=3, 
placebo n=0) and azathioprine (RTX n=2, placebo n=0).
§Current immunosuppressive treatment included high-dose (>15 mg/day) prednisone (RTX n=2, placebo n=0), methotrexate (RTX n=5, 
placebo n=3), plaquenil (RTX n=1, placebo n=1), mycophenolate mofetil (RTX=1, placebo n=1).
¶Extent of lung disease in HRCT was scored according to Goh criteria33; the extent was evaluated over five levels and averaged (origin 
of great vessels, main carina, pulmonary venous confluence, halfway between the third and fifth section, immediately above the right 
hemidiaphragm)
ANA, antinuclear antibody; dcSSc, diffuse cutaneous systemic sclerosis; DLCO, diffusing capacity of the lungs for carbon monoxide; FVC, 
forced vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; HRCT, high-resolution CT; LVEF, left ventricular ejection 
fraction; RTX, rituximab.
n=7/8 in placebo had stable lung involvement on 
HRCT (between −10% and +10% change in mean 
extent of lung involvement) and n=1/7 in RTX versus 
n=1/8 in placebo had worsening lung involvement 
on HRCT (+10% or more change in extent of lung 
involvement).
Analysis of change in AUC showed no significant differ-
ences in the mRSS, FVC and HAQ-DI between the groups 
(see online supplementary table S2). Within the first 
year, mean change from baseline to 12 months follow-up 
in mRSS was comparable between groups, with −1.4 for 
the RTX and −2.7 for the control group (difference 1.3; 
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Figure 2 Change in modified Rodnan skin sore, forced vital capacity, diffusing capacity of the lung and HealthAssessment 
Questionnaire during 24-month follow-up in patients with systemic sclerosis treated with rituximab (RTX) orplacebo. HAQ, 
Health Assessment Questionnaire; RTX, rituximab; mRSS, modified Rodnan Skin Score; predFVC, forced vitalcapacity, 
percentage of predicted; predDLCO, diffusing capacity of the lung, percentage of predicted. Dots indicate medians;error bars 
indicate ranges.
Figure 3 Change in mean extent of lung tissue and lung tissue with ground glass or reticular pattern involvement from 
baseline to 12 months follow-up in patients with systemic sclerosis. Vertical axis represent differences in Goh scores between 
baseline and 12 months for (from left to right): (1) mean extent of affected lung tissue, (2) GGO; mean extend of ground 
glass opacities, (3) mean extend of affected lung tissue with reticular pattern. At 12 months a non-significant trend in favour 
of rituximab was observed (mean change in lung involvement: -1.6% RTX group vs. +2.8% placebo group [p=0.28]). The 
beneficial effect in the rituximab group was explained by a decrease of ground glass opacities. RTX, rituximab; t0, baseline; 
t12, 12 months follow-up.
95% CI −3.4 to 6.2; p=0.55). For FVC and HAQ-DI, differ-
ences in AUC between baseline and 1 year were also 
insignificant. For FVC, there was a slight improvement 
with RTX and a slight deterioration with placebo (mean 
change AUC baseline to 12 months follow-up 0.6 for RTX 
and −0.4 for placebo, p=0.59). Also during the second 
year, no significant differences were observed in AUC 
for mRSS, FVC and HAQ-DI (see online supplementary 
table 2).
Efficacy analyses for the individual disease parameters 
were repeated excluding the two patients with disease 
duration of >24 months since diagnosis. These analyses 
did not show different results.
Recorded parameters reflecting vascular complications 
did not differ between the treatment arms: no patients 
in the trial had impaired kidney function and estimated 
glomelurar filtration rates (eGFR) within study arms were 
comparable (mean eGFR at T=0: placebo 118.5 mL/
min/1.73 m2, RTX 106.8 mL/min/1.73 m2) and were 
stable throughout the trial. Also LVEF (as measured by 
echocardiography) remained stable throughout the trial 
in all participants (mean LVEF at T=0: placebo 62.0%, 
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Figure 4 Improvement of lung involvement as evaluated 
by HRCT of a patient treated with rituximab. HRCT, high 
resolution computed tomography; inspiratory scan, halfway 
between pulmonary venous confluence and right hemi-
diaphrag. Upper HRCT: baseline HRCT, before rituximab use; 
lower HRCT: 12 months after initial gift of rituximab.
RTX 60.2%, at T=24: placebo 60.2%, RTX 65.5%). Digital 
ulcers occurred both in the placebo (n=3) and the ritux-
imab group (n=3).
In the analyses of SF-36 scores and EQ-5D scores, no 
differences were seen (data not shown).
Two patients in the placebo group showed disease 
progression during follow-up according to prespecified 
criteria, including the patient that died after dropout. 
In the rituximab group, one patient showed disease 
progression. Apart from the patient that died, study 
disease progression was based on a ≥30% increased 
mRSS relative to baseline at the 12-month (placebo, n=1) 
and 18-month visits (RTX, n=1) in both cases. Including 
the patient that died after dropout, there was no differ-
ence in progression-free survival between groups (log 
rank (Mantel-Cox) p=0.674). Also after excluding the 
two patients with disease duration of >24 months, there 
was no significant difference in progression-free survival 
between the groups.
safety and toxicity
No patients died during the study. One patient (placebo 
group) died due to disease progression, after dropout 
at 6 months because of active disease. This patient 
eventually died at 23 months due to scleroderma renal 
crisis after autologous haematopoietic stem cell trans-
plantation.
A total of 88 adverse events (AEs) occurred during 
the study: 52 in the RTX group (six grade 3 AEs, two 
grade 4 AEs) and 36 in the control group (seven grade 3 
AEs, zero grade 4 AEs) (p=0.22)(see online supplemen-
tary table S1). There were seven serious adverse events 
(SAEs) in the RTX group and four in the placebo group 
(p=0.36). SAEs in the RTX group were a breast carcinoma 
(18 months after first gift of RTX), abnormal cervical 
histology leading to hysterectomy (6 months after first 
gift of RTX; medical history of this patient mentioned 
abnormal cervical histology also before inclusion in the 
trial), an anaemia due to severe menstruation (7 months 
after first gift of RTX), a pancytopenia (12 months after 
first gift of RTX) and three events related to digital 
ulcers (n=2 at 1 month after first gift of RTX, the other 
at 7 months). SAEs in the placebo group included severe 
weight loss which required treatment by percutaneous 
endoscopic gastrostomy placement (17 months after first 
gift of RTX) and three events related to digital ulcers (1, 
14 and 18 months after initial RTX). There were more 
grade 1 AEs in the rituximab group due to mild infusion 
reactions (system organ class type: immune system). A 
clear causal relation between AEs and treatment with 
RTX could not be established, except for mild infusion 
reactions.
Immunophenotyping of peripheral blood mononuclear cells
At baseline, there were no differences seen in propor-
tions of macrophages (CD14+), NK cells (CD56+), T 
helper cells (CD3+/CD4+), cytotoxic T cells (CD3+/
CD8+) or B cells (CD19+) between placebo and ritux-
imab group (Data not shown). Three months after 
initial anti-CD20 treatment, significant depletion B cells 
was seen and simultaneously a decline in T cells was 
observed. Counterwise the proportion of macrophages 
increased.
When observing the different subsets of B cells during 
the study, as shown in figure 5, naïve and memory B 
cells were depleted 3 months after the first gift of RTX. 
In five of eight patients with rituximab, a reduction of 
CD19+CD20-CD27++ plasmablasts was seen. Reduction 
of plasmablasts was significant within the RTX group 
when compared with baseline, but insignificant when 
compared with the placebo at the same time point. When 
assessing depletion of immunoglobulin expressing (IgG, 
IgA, IgM and IgD) naïve (CD19+CD27-) and memory 
(CD19+CD27+) subsets, as a positive control, all subsets 
were depleted (data not shown). At time of consolida-
tion treatment (month 6), repopulation of naïve B cells, 
memory B cells and plasmablasts was present. However, 
throughout the complete follow-up period, repopulation 
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Figure 5 Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with 
systemic sclerosis. Indicated points resemble medians; Rituximab: T0, n= 8; T3 n=8; T6 n=7; T12 n=6; T24 n=4; Placebo: T0, 
n=8; T3, n=8; T6 n=8; T12 n=7; T24 n=7. Total events are defined as the number of detected cells by the flow cytometer. B cell 
depletion after rituximab treatment is seen in all B cell subsets.
of naïve B cells and memory B cells was incomplete in the 
RTX group (figure 5).
ELISPOT data are presented in online  supplemen-
tary figure 1, which shows persistence of plasma cells at 
month 3.
skin biopsies
Skin biopsies were performed in 15 patients (RTX n=7, 
placebo n=8) at baseline and in 14 patients (RTX n=7, 
placebo n=7) at 3 months (see online supplementary 
table S3). For three patients in the placebo group, and 
for one patient in the RTX group, skin was clinically 
unaffected at the site of biopsy. Interobserver agree-
ment of histological skin score evaluated by Fleiss’ kappa 
was κ=0.49 for T cells, κ=0.32 for B cells and κ=0.63 for 
macrophages.
There were no significant differences found in immune 
cell presence in skin neither between groups, nor within 
groups over time. At baseline there was a trend towards 
more mononuclear infiltration in the placebo group, 
based on the presence of more T cells. Over time, pres-
ence of T cells in the rituximab group increased at 3 
months compared with baseline. Presence of other 
immune cells was stable over time (see online supple-
mentary table S3).
B cells were rarely present in skin tissue, only one 
patient in the placebo group that showed a collection 
of >10 cells, but less than 50 cells at baseline. Scattered 
B cells (range 2–7 per biopsy) were seen in 5 out of 15 
biopsies at baseline (RTX n=3, placebo n=2). Over time, 
there were no changes in the presence of B cells in skin 
of RTX-treated patients, 3 months after initial gift, with B 
cells present in 4 out of 7 biopsies. This was identical to 
the number of placebo patients with B cell presence in 
skin at 3 months (4 out of 7).
dIscussIon
This small randomised, placebo-controlled trial cannot 
reject nor confirm the hypothesis of RTX preventing 
fibrotic complications. No major safety issues were 
observed with RTX in the subset of patients with early SSc. 
Immunologically, RTX achieved its presumed biological 
effect: a depletion of circulating B cells up to minimal 
counts, but with persistence of antigen-secreting cells 
and incomplete depletion of the CD27++ plasmablast 
compartment. No change in the small number of cells 
from the B cell lineage present in skin tissue was observed 
with RTX treatment. Over time, small, non-significant 
differences in FVC, extent of pulmonary involvement and 
HAQ-DI in favour of the RTX group were found. Further 
research must confirm the credibility of these findings. 
A larger scale RCT in patients with proven pulmonary 
involvement therefore seems plausible and feasible.
Unfortunately, the trial had recruitment problems 
resulting in premature termination of inclusion. More-
over, patients in the control group experienced an 
unexpected favourable disease course, which complicates 
firm conclusions about efficacy of RTX in preventing 
fibrotic complications. This study aimed to include 
patients with early dcSSc. Indeed, our placebo group 
included patients of which the majority had dcSSc at 
baseline (63%), and four of eight patients were either 
ATA or RNApIII positive. Both these antibodies are asso-
ciated with more severe disease course.43 44 Despite these 
characteristics reflecting high risk, early dcSSc, 75% of 
patients in the placebo group had favourable outcome 
after 2 years.
There is a small insignificant difference in disease dura-
tion between the RTX and the placebo group, with the 
placebo group having a longer disease duration. It has 
been shown that with longer disease duration, chances 
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to improve spontaneously slightly increase45 which might 
partially explain the beneficial disease course in placebo. 
However, excluding the two patients with the longest 
disease duration did not change our results.
Several case reports, open-label studies and a nested 
case–control study thus far reported a potential beneficial 
effect of RTX on pulmonary function, skin fibrosis and 
functional impairment in SSc.12–21 46–49 Our observations 
are in line with the study from Lafyatis,15 who treated 15 
patients with early SSc with RTX and did not find a clear 
beneficial effect on skin fibrosis and pulmonary function 
at 6 and 12 months of follow-up. Various explanations 
can account for the difference between previous open-
label studies and our findings. As these studies did not 
include a placebo group, part of the observed efficacy 
might reflect natural disease course. In addition, most 
open-label studies included patients with longer disease 
duration13 14 50 and thus possibly selected an immunologi-
cally different subgroup of SSc patients. In comparison to 
the open-label studies of Lafyatis et al and Smith et al,15 17 
who both also included patients with early disease, mean 
skin scores were lower in our population, which compli-
cates the possibility of demonstrating clear clinical 
efficacy on skin involvement. When analysing only the 
patients with dcSSc at baseline, RTX n=3/7 showed a 
decrease in mRSS >5 versus n=2/5 within the placebo 
group. On the other hand, it is known that patients with 
more skin fibrosis at baseline are more likely to regress 
even without therapy over the next year.51
Immunophenotyping of peripheral blood showed 
almost complete B cell depletion, which is in line with 
previous studies.15 17 It is known that during treatment 
with RTX, plasmablasts and plasma cells can persist.52 
Besides confirming this with ELISPOT, thereby showing 
persistence of IgA, IgG and IgM antigen-secreting cells 
after treatment with RTX, this is also demonstrated by 
the incomplete depletion of the CD27++ plasmablast 
compartment (see online supplementary figure S1). 
Other studies found CD20-positive B cells in skin biop-
sies in approximately half of patients at baseline and 
depletion in most of these cases.12 13 17 To overcome 
possible interference of RTX treatment with detection 
of CD20-positive B cells in skin, we chose to use CD79a 
staining on skin, which also stains plasmablasts and 
plasma cells that lack CD20, while in previous studies, 
CD20 staining was used. Based on morphology, the 
persisting B cells in our samples could reflect unaffected 
long-lived B cell populations. The exact nature and the 
relevance of these persistent B cells for development and 
persistence of skin fibrosis remains to be determined, 
and might be relevant in determining subsets of patients 
with SSc with high likelihood of responding to RTX.
Remarkably, two out of eight RTX-treated patients 
showed evident improvement of the extent of ground 
glass opacities in HRCT at 1 year follow-up versus none 
of the placebo-treated patients. Radiological improve-
ment of CTD-associated and RA-ILD after treatment with 
RTX has also been described by other authors.53 54 Out of 
interest, and to possibly guide future research in the field, 
we compared different B cell subsets in baseline PBMCs 
between RTX patients with pulmonary improvement 
and those without. RTX-treated patients with pulmonary 
improvement both had higher counts of naïve B cells 
(CD19+,CD27-) (mean CD19+CD27+ of n=2 non-im-
provers under RTX 1.8% of total events vs n=6 improvers 
under RTX 5.6% of total events, p=0.003), while other 
subsets were comparable. We speculate that this subgroup 
of patients, possibly reflecting those with very early and 
active inflammatory pulmonary involvement, might be 
the subset of patients most likely to benefit from B cell 
depleting therapy. However, these observations obviously 
await replication.
In conclusion, we performed a double-blind place-
bo-controlled trial in patients with early SSc and show 
in-depth analysis of B cells in peripheral blood and skin 
tissue. Although given the small sample size and the unex-
pected favourable disease course in the placebo group, 
no firm conclusions on clinical efficacy of rituximab in 
early SSc can be drawn; our data show that a larger RCT 
in early SSc with proven pulmonary involvement might 
be worthwhile. In addition, inclusion of peripheral blood 
and skin tissue analyses is also warranted in future trials 
to determine the nature, role and relevance of persisting 
B cells in skin, and persisting plasmablasts and plasma 
cells in peripheral blood. Analysis as presented herein 
might help to identify a subset of patients with SSc most 
likely to benefit from B cell-depleting therapies.
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